Neither COVID-19, Nor Cryopreservation, Prevented Allogeneic Product Infusion: A Report from the National Marrow Donor Program

Mostrar otras versiones (1)

The COVID-19 pandemic posed numerous logistical challenges in the way that the National Marrow Donor Program (NMDP) delivered allogeneic products to patients undergoing hematopoietic cell transplant (HCT). Prior to COVID-19, fresh bone marrow (BM) and peripheral blood stem cell (PBSC) grafts were in...

Descripción completa

Detalles Bibliográficos
Autores principales: Stefanski, Heather E., Newman, Jeni, Novakovich, Jennifer, Barten, Jacklyn, Oakes, Jason, Cody, Meghann, Pham, Huy P, Auletta, Jeffery, Miller, John P., Devine, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
711.Cell Collection and Processing
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701604/
http://dx.doi.org/10.1182/blood-2021-152952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701604/
http://dx.doi.org/10.1182/blood-2021-152952

Ejemplares similares